Intercept failed NASH candidate precipitated Alfasigma acquisition

Mohammed Haneefa Nizamudeen

After the

failure of Intercept Pharmaceuticals’ (ICPT) Ocaliva (obeticolic acid) for nonalcoholic steatohepatitis (NASH) in June, the company was destined to be acquired.

GlobalData argues that without any other late-stage candidates in its pipeline and with its share price

Source link

Related Articles

Back to top button